Department of Infectious Diseases, Beijing You an Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, 100069, People's Republic of China.
Department of Respiratory and Infectious Diseases, Beijing You an Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, 100069, People's Republic of China.
Drug Des Devel Ther. 2021 Mar 17;15:1213-1223. doi: 10.2147/DDDT.S293216. eCollection 2021.
Severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2) is an emerging pathogen, which is similar to previous SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) occurrences. However, we only get few understandings about the pathogenesis of SARS-CoV-2, which need to further be studied. The discovery of an agent that has a treatment efficacy against SARS-CoV-2 is very urgent. In this review, we briefly discuss the virology of this pathogen and focus on the available understanding of the pathogenesis and treatments of this pathogen including the uses of nucleoside analogues, protease inhibitors, interferons, and other small-molecule drugs, on the basis previous comprehensions of SARS and MERS. These reviewed concepts may be beneficial in providing new insights and potential treatments for COVID-19.
严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）是一种新兴病原体，与之前的严重急性呼吸系统综合征冠状病毒（SARS-CoV）和中东呼吸系统综合征冠状病毒（MERS-CoV）的发生类似。然而，我们对 SARS-CoV-2 的发病机制只有很少的了解，需要进一步研究。发现一种对 SARS-CoV-2 有治疗效果的药物迫在眉睫。在这篇综述中，我们简要讨论了这种病原体的病毒学，并在前人对 SARS 和 MERS 的全面了解的基础上，重点介绍了对该病原体发病机制和治疗方法的现有认识，包括核苷类似物、蛋白酶抑制剂、干扰素和其他小分子药物的应用。这些综述的概念可能有助于为 COVID-19 提供新的见解和潜在的治疗方法。
